Boehringer, Hospira Products Adulterated, FDA Warns

Law360, Los Angeles (May 21, 2013, 4:34 PM EDT) -- The U.S. Food and Drug Administration on Tuesday released warning letters it sent to generic-drug maker Hospira Inc. and German pharmaceutical company Boehringer-Ingelheim Pharma GmbH & Co. KG warning the companies of several products that are considered adulterated due to inadequate manufacturing processes.

The letters, sent to Boehringer and Hospira on May 6 and May 9, respectively, outline various violations of current good manufacturing practice stemming from the inspections of a Boehringer manufacturing facility in Germany and Hospira’s firm in Illinois.

The FDA says a November...
To view the full article, register now.